{"id":"comparator-rizatriptan","safety":{"commonSideEffects":[{"rate":"9","effect":"Dizziness"},{"rate":"8","effect":"Somnolence"},{"rate":"5","effect":"Asthenia/fatigue"},{"rate":"2","effect":"Chest pain/pressure"},{"rate":"1","effect":"Palpitations"},{"rate":"6","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201032","moleculeType":"Small molecule","molecularWeight":"391.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rizatriptan binds to 5-HT1B and 5-HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. This causes vasoconstriction of dilated cranial arteries and reduces the release of vasoactive neuropeptides involved in migraine pathophysiology, thereby terminating acute migraine attacks.","oneSentence":"Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:14.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults"}]},"trialDetails":[{"nctId":"NCT00111722","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00095004","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-10-21","conditions":"Migraine","enrollment":167},{"nctId":"NCT00111709","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00092963","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-08-17","conditions":"Migraine","enrollment":529},{"nctId":"NCT00812006","phase":"PHASE3","title":"A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-03-24","conditions":"Migraine","enrollment":108},{"nctId":"NCT00894556","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-06-10","conditions":"Acute Migraine","enrollment":109},{"nctId":"NCT00516737","phase":"PHASE3","title":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10-03","conditions":"Migraine","enrollment":207},{"nctId":"NCT00899379","phase":"PHASE3","title":"Treatment of Multiple Attacks of Acute Migraine (0462-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":"Migraine Headache","enrollment":473},{"nctId":"NCT00898677","phase":"PHASE3","title":"Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-09","conditions":"Migraine Headache","enrollment":1268},{"nctId":"NCT00250458","phase":"PHASE3","title":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Migraine","enrollment":346},{"nctId":"NCT00897949","phase":"PHASE3","title":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-03","conditions":"Migraine Headache","enrollment":1473},{"nctId":"NCT00897104","phase":"PHASE3","title":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-08","conditions":"Migraine Headache","enrollment":933},{"nctId":"NCT00246337","phase":"PHASE2","title":"A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-11","conditions":"Migraine","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":267,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: Rizatriptan","genericName":"Comparator: Rizatriptan","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}